Companies /Healthcare

PepGen Inc

NASDAQ: PEPG Biotechnology
$2.42
▲ $0.08 (+3.42%) today
Markets closed · 9:35am ET

Fundamentals

Market Cap
$162.1M
EPS (TTM)
$-1.00
52-Week Range
$1 – $8
Street Target
$10.19

About PepGen

PepGen Inc. is a pioneering biotechnology firm based in Boston, Massachusetts, dedicated to advancing the treatment of severe neuromuscular and neurologic diseases. With a focus on oligonucleotide therapeutics, its flagship product, PGN-EDO51, is currently undergoing Phase I clinical trials aimed at combating Duchenne muscular dystrophy. Additionally, PepGen is exploring treatments for myotonic dystrophy type 1 and other forms of muscular dystrophy, demonstrating its commitment to addressing unmet medical needs in the neuromuscular field since its inception in 2018.

PEPG Coverage